RIG‐I is a pattern‐recognition receptor on the cell membrane that has been proposed as a target for psoriasis treatment.29 In addition, coencapsulation of RIG‐I‐specific ligands and antigenic peptides decreases the growth rate of cells in patients with colorectal cancer and can prevent liver metastases.29 PUVA has been shown to activate RIG‐I and promote apoptosis in skin cancer cells.30 However, the role of RIG‐I in NPC has not been reported. The gene discussed is RIGI; the disease is psoriasis.